Table 3.
Adverse events in the levofluxacin and clarithromycin based sequential therapy
| P value | CI(95%) | OR | Cla-seq group N (%) | Lev-seq group N (%) | Variables |
|---|---|---|---|---|---|
| 0.084 | 0.856-1.04 | 1.608 | 8(8.3%) | 13(13.4%) | Nausea |
| 0.505 | 0.254-4.43 | 1.485 | 2(2.10%) | 3(3.1%) | Vomiting |
| 0.494 | 0.171-0.322 | 0.742 | 4(4.2%) | 3(3.1%) | Diarrhea |
| 0.492 | 0.327-2.29 | 0.866 | 8(8.3%) | 7(7.2%) | Abdominal pain |
| 0.354 | 0.205-4.78 | 0.990 | 3(3.1%) | 3(3.1%) | Constipation |
| 0.490 | 0.354-2.18 | 0.880 | 9(9.4%) | 8(8.2%) | Anorexia |
| 0.261 | - | - | 0(0%) | 2(2.1%) | Rash |
| 0. 09 | 0.614.4.89 | 2.992 | 2(2.1%) | 6(6.2%) | Headache |
| 0.492 | .296 -2.95 | 0. 848 | 7(7.3%) | 6(6.2%) | Bad taste |
| 0.115 | 0.734-1.99 | 1.09 | 1(1.1%) | 2(2.1%) | Patient who withdrew |
| 0.651 | 0.385-3.13 | 1.78 | 96(100%) | 97(100%) | Good compliance |